Michael Hayden Publications

  1. Ellrichmann, G, Blusch, A, Fatoba, O, Brunner, J, Hayardeny, L, Hayden, M et al.. Laquinimod treatment in the R6/2 mouse model. Sci Rep. 2017;7 (1):4947. doi: 10.1038/s41598-017-04990-1. PubMed PMID:28694434 PubMed Central PMC5504033.
  2. Ross, CJ, Towfic, F, Shankar, J, Laifenfeld, D, Thoma, M, Davis, M et al.. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. Genome Med. 2017;9 (1):50. doi: 10.1186/s13073-017-0436-y. PubMed PMID:28569182 PubMed Central PMC5450152.
  3. Drögemöller, BI, Monzon, JG, Bhavsar, AP, Borrie, AE, Brooks, B, Wright, GEB et al.. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. JAMA Oncol. 2017; :. doi: 10.1001/jamaoncol.2017.0502. PubMed PMID:28448657 .
  4. Martin, DDO, Hayden, MR. Neurodegeneration: Role of repeats in protein clearance. Nature. 2017;545 (7652):33-34. doi: 10.1038/nature22489. PubMed PMID:28445458 .
  5. Lambinet, V, Hayden, ME, Reigl, K, Gomis, S, Gries, G. Linking magnetite in the abdomen of honey bees to a magnetoreceptive function. Proc. Biol. Sci. 2017;284 (1851):. doi: 10.1098/rspb.2016.2873. PubMed PMID:28330921 PubMed Central PMC5378088.
  6. Aminkeng, F, Ross, CJD, Rassekh, SR, Rieder, MJ, Bhavsar, AP, Sanatani, S et al.. Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. Br J Clin Pharmacol. 2017;83 (5):1143-1145. doi: 10.1111/bcp.13218. PubMed PMID:28317142 PubMed Central PMC5401971.
  7. Naia, L, Cunha-Oliveira, T, Rodrigues, J, Rosenstock, TR, Oliveira, A, Ribeiro, M et al.. Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease. J. Neurosci. 2017;37 (10):2776-2794. doi: 10.1523/JNEUROSCI.2006-14.2016. PubMed PMID:28123081 .
  8. Southwell, AL, Skotte, NH, Villanueva, EB, Østergaard, ME, Gu, X, Kordasiewicz, HB et al.. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Hum. Mol. Genet. 2017;26 (6):1115-1132. doi: 10.1093/hmg/ddx021. PubMed PMID:28104789 .
  9. Hayden, MR, Kay, C. Author response: Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2017;88 (3):334-335. doi: 10.1212/WNL.0000000000003528. PubMed PMID:28093515 .
  10. Kay, C, Tirado-Hurtado, I, Cornejo-Olivas, M, Collins, JA, Wright, G, Inca-Martinez, M et al.. The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America. Eur. J. Hum. Genet. 2017;25 (3):332-340. doi: 10.1038/ejhg.2016.169. PubMed PMID:28000697 PubMed Central PMC5315506.
  11. Sanders, SS, Parsons, MP, Mui, KK, Southwell, AL, Franciosi, S, Cheung, D et al.. Sudden death due to paralysis and synaptic and behavioral deficits when Hip14/Zdhhc17 is deleted in adult mice. BMC Biol. 2016;14 (1):108. doi: 10.1186/s12915-016-0333-7. PubMed PMID:27927242 PubMed Central PMC5142322.
  12. Skotte, NH, Sanders, SS, Singaraja, RR, Ehrnhoefer, DE, Vaid, K, Qiu, X et al.. Palmitoylation of caspase-6 by HIP14 regulates its activation. Cell Death Differ. 2017;24 (3):433-444. doi: 10.1038/cdd.2016.139. PubMed PMID:27911442 PubMed Central PMC5344205.
  13. Ryskamp, D, Wu, J, Geva, M, Kusko, R, Grossman, I, Hayden, M et al.. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol. Dis. 2017;97 (Pt A):46-59. doi: 10.1016/j.nbd.2016.10.006. PubMed PMID:27818324 PubMed Central PMC5214572.
  14. Wright, GE, Carleton, B, Hayden, MR, Ross, CJ. The global spectrum of protein-coding pharmacogenomic diversity. Pharmacogenomics J. 2016; :. doi: 10.1038/tpj.2016.77. PubMed PMID:27779249 .
  15. Jan, A, Jansonius, B, Delaidelli, A, Somasekharan, SP, Bhanshali, F, Vandal, M et al.. eEF2K inhibition blocks Aβ42 neurotoxicity by promoting an NRF2 antioxidant response. Acta Neuropathol. 2017;133 (1):101-119. doi: 10.1007/s00401-016-1634-1. PubMed PMID:27752775 .
  16. Kaye, J, Piryatinsky, V, Birnberg, T, Hingaly, T, Raymond, E, Kashi, R et al.. Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. U.S.A. 2016;113 (41):E6145-E6152. doi: 10.1073/pnas.1607843113. PubMed PMID:27671624 PubMed Central PMC5068259.
  17. Naia, L, Rosenstock, TR, Oliveira, AM, Oliveira-Sousa, SI, Caldeira, GL, Carmo, C et al.. Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington's Disease Models. Mol. Neurobiol. 2016; :. doi: 10.1007/s12035-016-0048-3. PubMed PMID:27590140 .
  18. Garcia-Miralles, M, Hong, X, Tan, LJ, Caron, NS, Huang, Y, To, XV et al.. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep. 2016;6 :31652. doi: 10.1038/srep31652. PubMed PMID:27528441 PubMed Central PMC4985819.
  19. Geva, M, Kusko, R, Soares, H, Fowler, KD, Birnberg, T, Barash, S et al.. Pridopidine activates neuroprotective pathways impaired in Huntington Disease. Hum. Mol. Genet. 2016;25 (18):3975-3987. doi: 10.1093/hmg/ddw238. PubMed PMID:27466197 PubMed Central PMC5291233.
  20. Southwell, AL, Smith-Dijak, A, Kay, C, Sepers, M, Villanueva, EB, Parsons, MP et al.. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Hum. Mol. Genet. 2016;25 (17):3654-3675. doi: 10.1093/hmg/ddw212. PubMed PMID:27378694 PubMed Central PMC5216613.
  21. Kay, C, Collins, JA, Miedzybrodzka, Z, Madore, SJ, Gordon, ES, Gerry, N et al.. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2016;87 (3):282-8. doi: 10.1212/WNL.0000000000002858. PubMed PMID:27335115 PubMed Central PMC4955276.
  22. Ehrnhoefer, DE, Caron, NS, Deng, Y, Qiu, X, Tsang, M, Hayden, MR et al.. Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. Exp. Neurol. 2016;283 (Pt A):121-8. doi: 10.1016/j.expneurol.2016.06.008. PubMed PMID:27296315 .
  23. Hayden, M. A true mentor and pioneer in medical genetics. S. Afr. Med. J. 2016;106 (6 Suppl 1):S7-9. . PubMed PMID:27245547 .
  24. Aminkeng, F, Ross, CJ, Rassekh, SR, Hwang, S, Rieder, MJ, Bhavsar, AP et al.. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016;82 (3):683-95. doi: 10.1111/bcp.13008. PubMed PMID:27197003 PubMed Central PMC5338111.
  25. Masellis, M, Collinson, S, Freeman, N, Tampakeras, M, Levy, J, Tchelet, A et al.. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. Brain. 2016;139 (Pt 7):2050-62. doi: 10.1093/brain/aww109. PubMed PMID:27190009 .
  26. Maillet, A, Tan, K, Chai, X, Sadananda, SN, Mehta, A, Ooi, J et al.. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes. Sci Rep. 2016;6 :25333. doi: 10.1038/srep25333. PubMed PMID:27142468 PubMed Central PMC4855185.
  27. Teo, RT, Hong, X, Yu-Taeger, L, Huang, Y, Tan, LJ, Xie, Y et al.. Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. Hum. Mol. Genet. 2016;25 (13):2621-2632. doi: 10.1093/hmg/ddw122. PubMed PMID:27126634 PubMed Central PMC5181633.
  28. Connolly, C, Magnusson-Lind, A, Lu, G, Wagner, PK, Southwell, AL, Hayden, MR et al.. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin. Neuroscience. 2016;325 :74-88. doi: 10.1016/j.neuroscience.2016.03.031. PubMed PMID:27033979 .
  29. Miniarikova, J, Zanella, I, Huseinovic, A, van der Zon, T, Hanemaaijer, E, Martier, R et al.. Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease. Mol Ther Nucleic Acids. 2016;5 :e297. doi: 10.1038/mtna.2016.7. PubMed PMID:27003755 PubMed Central PMC5014463.
  30. Wijesekara, N, Kaur, A, Westwell-Roper, C, Nackiewicz, D, Soukhatcheva, G, Hayden, MR et al.. ABCA1 deficiency and cellular cholesterol accumulation increases islet amyloidogenesis in mice. Diabetologia. 2016;59 (6):1242-6. doi: 10.1007/s00125-016-3907-6. PubMed PMID:26970755 .
  31. Grossman, I, Knappertz, V, Laifenfeld, D, Ross, C, Zeskind, B, Kolitz, S et al.. Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research. Prog. Neurobiol. 2017;152 :114-130. doi: 10.1016/j.pneurobio.2016.02.001. PubMed PMID:26952809 .
  32. Riechers, SP, Butland, S, Deng, Y, Skotte, N, Ehrnhoefer, DE, Russ, J et al.. Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD. Hum. Mol. Genet. 2016;25 (8):1600-18. doi: 10.1093/hmg/ddw036. PubMed PMID:26908611 .
  33. Naia, L, Ribeiro, M, Rodrigues, J, Duarte, AI, Lopes, C, Rosenstock, TR et al.. Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin. Neuropeptides. 2016;58 :73-81. doi: 10.1016/j.npep.2016.01.009. PubMed PMID:26876526 .
  34. Garcia-Miralles, M, Ooi, J, Ferrari Bardile, C, Tan, LJ, George, M, Drum, CL et al.. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Exp. Neurol. 2016;278 :4-10. doi: 10.1016/j.expneurol.2016.01.019. PubMed PMID:26825854 .
  35. Dobson, L, Träger, U, Farmer, R, Hayardeny, L, Loupe, P, Hayden, MR et al.. Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. J. Neurochem. 2016;137 (5):782-94. doi: 10.1111/jnc.13553. PubMed PMID:26823290 PubMed Central PMC4982105.
  36. Hasson, T, Kolitz, S, Towfic, F, Laifenfeld, D, Bakshi, S, Beriozkin, O et al.. Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. J. Neuroimmunol. 2016;290 :84-95. doi: 10.1016/j.jneuroim.2015.11.020. PubMed PMID:26711576 .
  37. Chan, SL, Samaranayake, N, Ross, CJ, Toh, MT, Carleton, B, Hayden, MR et al.. Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. Pharmacogenet. Genomics. 2016;26 (1):28-39. doi: 10.1097/FPC.0000000000000182. PubMed PMID:26444257 PubMed Central PMC4890825.
  38. Patankar, JV, Brunham, LR, Hayden, MR. Comment on Rickels et al. Loss-of-Function Mutations in ABCA1 and Enhanced β-Cell Secretory Capacity in Young Adults. Diabetes 2015;64:193-199. Diabetes. 2015;64 (9):e25-6; discussion e27. doi: 10.2337/db15-0518. PubMed PMID:26294435 .
  39. Sanders, SS, Martin, DD, Butland, SL, Lavallée-Adam, M, Calzolari, D, Kay, C et al.. Curation of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases and Disorders of the Nervous System and Cancers. PLoS Comput. Biol. 2015;11 (8):e1004405. doi: 10.1371/journal.pcbi.1004405. PubMed PMID:26275289 PubMed Central PMC4537140.
  40. Sadananda, SN, Foo, JN, Toh, MT, Cermakova, L, Trigueros-Motos, L, Chan, T et al.. Targeted next-generation sequencing to diagnose disorders of HDL cholesterol. J. Lipid Res. 2015;56 (10):1993-2001. doi: 10.1194/jlr.P058891. PubMed PMID:26255038 PubMed Central PMC4583092.
  41. Aminkeng, F, Bhavsar, AP, Visscher, H, Rassekh, SR, Li, Y, Lee, JW et al.. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat. Genet. 2015;47 (9):1079-84. doi: 10.1038/ng.3374. PubMed PMID:26237429 PubMed Central PMC4552570.
  42. Visscher, H, Rassekh, SR, Sandor, GS, Caron, HN, van Dalen, EC, Kremer, LC et al.. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics. 2015;16 (10):1065-76. doi: 10.2217/pgs.15.61. PubMed PMID:26230641 .
  43. Kay, C, Collins, JA, Skotte, NH, Southwell, AL, Warby, SC, Caron, NS et al.. Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry. Mol. Ther. 2015;23 (11):1759-71. doi: 10.1038/mt.2015.128. PubMed PMID:26201449 PubMed Central PMC4817952.
  44. Shaw, K, Amstutz, U, Kim, RB, Lesko, LJ, Turgeon, J, Michaud, V et al.. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Ther Drug Monit. 2015;37 (4):428-36. doi: 10.1097/FTD.0000000000000192. PubMed PMID:26186657 .
  45. Southwell, AL, Smith, SE, Davis, TR, Caron, NS, Villanueva, EB, Xie, Y et al.. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci Rep. 2015;5 :12166. doi: 10.1038/srep12166. PubMed PMID:26174131 PubMed Central PMC4502413.
  46. Hitchcock, E, Patankar, JV, Tyson, C, Hrynchak, M, Hayden, MR, Gibson, WT et al.. A novel microdeletion affecting the CETP gene raises HDL-associated cholesterol levels. Clin. Genet. 2015; :. doi: 10.1111/cge.12633. PubMed PMID:26126777 .
  47. Kolitz, S, Hasson, T, Towfic, F, Funt, JM, Bakshi, S, Fowler, KD et al.. Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids. Sci Rep. 2015;5 :10191. doi: 10.1038/srep10191. PubMed PMID:25998228 PubMed Central PMC4441120.
  48. Jan, A, Karasinska, JM, Kang, MH, de Haan, W, Ruddle, P, Kaur, A et al.. Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression. [Corrected]. Neurosci. Lett. 2015;598 :66-72. doi: 10.1016/j.neulet.2015.05.007. PubMed PMID:25957561 .
  49. Bečanović, K, Nørremølle, A, Neal, SJ, Kay, C, Collins, JA, Arenillas, D et al.. A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease. Nat. Neurosci. 2015;18 (6):807-16. doi: 10.1038/nn.4014. PubMed PMID:25938884 .
  50. Stroedicke, M, Bounab, Y, Strempel, N, Klockmeier, K, Yigit, S, Friedrich, RP et al.. Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity. Genome Res. 2015;25 (5):701-13. doi: 10.1101/gr.182444.114. PubMed PMID:25908449 PubMed Central PMC4417118.
  51. Martin, DD, Hayden, MR. Post-translational myristoylation at the cross roads of cell death, autophagy and neurodegeneration. Biochem. Soc. Trans. 2015;43 (2):229-34. doi: 10.1042/BST20140281. PubMed PMID:25849922 .
  52. Sanders, SS, Hayden, MR. Aberrant palmitoylation in Huntington disease. Biochem. Soc. Trans. 2015;43 (2):205-10. doi: 10.1042/BST20140242. PubMed PMID:25849918 .
  53. Mattis, VB, Tom, C, Akimov, S, Saeedian, J, Østergaard, ME, Southwell, AL et al.. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum. Mol. Genet. 2015;24 (11):3257-71. doi: 10.1093/hmg/ddv080. PubMed PMID:25740845 PubMed Central PMC4424959.
  54. Sturrock, A, Laule, C, Wyper, K, Milner, RA, Decolongon, J, Dar Santos, R et al.. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Mov. Disord. 2015;30 (3):393-401. doi: 10.1002/mds.26118. PubMed PMID:25690257 .
  55. Southwell, AL, Franciosi, S, Villanueva, EB, Xie, Y, Winter, LA, Veeraraghavan, J et al.. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 2015;76 :46-56. doi: 10.1016/j.nbd.2015.01.002. PubMed PMID:25662335 .
  56. Østergaard, ME, Thomas, G, Koller, E, Southwell, AL, Hayden, MR, Seth, PP et al.. Biophysical and biological characterization of hairpin and molecular beacon RNase H active antisense oligonucleotides. ACS Chem. Biol. 2015;10 (5):1227-33. doi: 10.1021/cb500880f. PubMed PMID:25654188 .
  57. Aharony, I, Ehrnhoefer, DE, Shruster, A, Qiu, X, Franciosi, S, Hayden, MR et al.. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Hum. Mol. Genet. 2015;24 (9):2604-14. doi: 10.1093/hmg/ddv023. PubMed PMID:25616965 PubMed Central PMC4383866.
  58. Brunham, LR, Hayden, MR. Human genetics of HDL: Insight into particle metabolism and function. Prog. Lipid Res. 2015;58 :14-25. doi: 10.1016/j.plipres.2015.01.001. PubMed PMID:25601427 .
  59. Wong, BK, Ehrnhoefer, DE, Graham, RK, Martin, DD, Ladha, S, Uribe, V et al.. Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. Neurobiol. Dis. 2015;76 :24-36. doi: 10.1016/j.nbd.2014.12.030. PubMed PMID:25583186 .
  60. Bates, GP, Dorsey, R, Gusella, JF, Hayden, MR, Kay, C, Leavitt, BR et al.. Huntington disease. Nat Rev Dis Primers. 2015;1 :15005. doi: 10.1038/nrdp.2015.5. PubMed PMID:27188817 .
  61. Sanders, SS, Hou, J, Sutton, LM, Garside, VC, Mui, KK, Singaraja, RR et al.. Huntingtin interacting proteins 14 and 14-like are required for chorioallantoic fusion during early placental development. Dev. Biol. 2015;397 (2):257-66. doi: 10.1016/j.ydbio.2014.11.018. PubMed PMID:25478910 .
  62. Semaka, A, Kay, C, Belfroid, RD, Bijlsma, EK, Losekoot, M, van Langen, IM et al.. A new mutation for Huntington disease following maternal transmission of an intermediate allele. Eur J Med Genet. 2015;58 (1):28-30. doi: 10.1016/j.ejmg.2014.11.005. PubMed PMID:25464109 .
  63. Ooi, J, Hayden, MR, Pouladi, MA. Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease. Mol. Neurobiol. 2015;52 (3):1850-1861. doi: 10.1007/s12035-014-8974-4. PubMed PMID:25398695 PubMed Central PMC4586002.
  64. Kaur, A, Patankar, JV, de Haan, W, Ruddle, P, Wijesekara, N, Groen, AK et al.. Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1. Diabetes. 2015;64 (4):1168-79. doi: 10.2337/db14-0716. PubMed PMID:25338812 .
  65. Brunham, LR, Kang, MH, Van Karnebeek, C, Sadananda, SN, Collins, JA, Zhang, LH et al.. Clinical, Biochemical, and Molecular Characterization of Novel Mutations in ABCA1 in Families with Tangier Disease. JIMD Rep. 2015;18 :51-62. doi: 10.1007/8904_2014_348. PubMed PMID:25308558 PubMed Central PMC4361929.
  66. Martin, DD, Ladha, S, Ehrnhoefer, DE, Hayden, MR. Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci. 2015;38 (1):26-35. doi: 10.1016/j.tins.2014.09.003. PubMed PMID:25282404 .
  67. Carleton, BC, Ross, CJ, Pussegoda, K, Bhavsar, AP, Visscher, H, Lee, JW et al.. Genetic markers of cisplatin-induced hearing loss in children. Clin. Pharmacol. Ther. 2014;96 (3):296-8. doi: 10.1038/clpt.2014.92. PubMed PMID:25141953 .
  68. Brown, AM, Renaud, Y, Ross, C, Hansen, M, Mongrain, I, Valois, D et al.. Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics. 2014;15 (9):1185-95. doi: 10.2217/pgs.14.81. PubMed PMID:25141894 .
  69. Kolitz, SE, Towfic, F, Grossman, I, Hayden, MR, Zeskind, B. Use of genetic technologies to compare medicines. Clin. Genet. 2014;86 (5):441-6. doi: 10.1111/cge.12462. PubMed PMID:25046029 .
  70. de Haan, W, Karasinska, JM, Ruddle, P, Hayden, MR. Hepatic ABCA1 expression improves β-cell function and glucose tolerance. Diabetes. 2014;63 (12):4076-82. doi: 10.2337/db14-0548. PubMed PMID:25028523 .
  71. Pitarokoili, K, Ambrosius, B, Schrewe, L, Hayardeny, L, Hayden, M, Gold, R et al.. Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis. J. Neuroimmunol. 2014;274 (1-2):38-45. doi: 10.1016/j.jneuroim.2014.06.012. PubMed PMID:25005118 .
  72. Rinninger, F, Heine, M, Singaraja, R, Hayden, M, Brundert, M, Ramakrishnan, R et al.. High density lipoprotein metabolism in low density lipoprotein receptor-deficient mice. J. Lipid Res. 2014;55 (9):1914-24. doi: 10.1194/jlr.M048819. PubMed PMID:24954421 PubMed Central PMC4617360.
  73. Singaraja, RR, Tietjen, I, Hovingh, GK, Franchini, PL, Radomski, C, Wong, K et al.. Identification of four novel genes contributing to familial elevated plasma HDL cholesterol in humans. J. Lipid Res. 2014;55 (8):1693-701. doi: 10.1194/jlr.M048710. PubMed PMID:24891332 PubMed Central PMC4109763.
  74. Brunham, LR, Chan, SL, Li, R, Aminkeng, F, Liu, X, Saw, WY et al.. Pharmacogenomic diversity in Singaporean populations and Europeans. Pharmacogenomics J. 2014;14 (6):555-63. doi: 10.1038/tpj.2014.22. PubMed PMID:24861855 .
  75. Zhang, SC, Bruce, C, Hayden, M, Rieder, MJ. Public perceptions of pharmacogenetics. Pediatrics. 2014;133 (5):e1258-67. doi: 10.1542/peds.2013-1416. PubMed PMID:24777223 .
  76. Carleton, BC, Ross, CJ, Bhavsar, AP, Lee, JW, Visscher, H, Rassekh, SR et al.. Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity". Clin. Pharmacol. Ther. 2014;96 (2):158. doi: 10.1038/clpt.2014.90. PubMed PMID:24755913 .
  77. Lam, J, Woodall, KL, Solbeck, P, Ross, CJ, Carleton, BC, Hayden, MR et al.. Codeine-related deaths: The role of pharmacogenetics and drug interactions. Forensic Sci. Int. 2014;239 :50-6. doi: 10.1016/j.forsciint.2014.03.018. PubMed PMID:24747667 .
  78. Kolodziejczyk, K, Parsons, MP, Southwell, AL, Hayden, MR, Raymond, LA. Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease. PLoS ONE. 2014;9 (4):e94562. doi: 10.1371/journal.pone.0094562. PubMed PMID:24728353 PubMed Central PMC3984157.
  79. Butland, SL, Sanders, SS, Schmidt, ME, Riechers, SP, Lin, DT, Martin, DD et al.. The palmitoyl acyltransferase HIP14 shares a high proportion of interactors with huntingtin: implications for a role in the pathogenesis of Huntington's disease. Hum. Mol. Genet. 2014;23 (15):4142-60. doi: 10.1093/hmg/ddu137. PubMed PMID:24705354 PubMed Central PMC4082372.
  80. Lee, JW, Aminkeng, F, Bhavsar, AP, Shaw, K, Carleton, BC, Hayden, MR et al.. The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin. Genet. 2014;86 (1):21-8. doi: 10.1111/cge.12392. PubMed PMID:24684508 PubMed Central PMC4233969.
  81. Sanders, SS, Mui, KK, Sutton, LM, Hayden, MR. Identification of binding sites in Huntingtin for the Huntingtin Interacting Proteins HIP14 and HIP14L. PLoS ONE. 2014;9 (2):e90669. doi: 10.1371/journal.pone.0090669. PubMed PMID:24651384 PubMed Central PMC3947954.
  82. Kay, C, Skotte, NH, Southwell, AL, Hayden, MR. Personalized gene silencing therapeutics for Huntington disease. Clin. Genet. 2014;86 (1):29-36. doi: 10.1111/cge.12385. PubMed PMID:24646433 .
  83. Rotblat, B, Southwell, AL, Ehrnhoefer, DE, Skotte, NH, Metzler, M, Franciosi, S et al.. HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. Proc. Natl. Acad. Sci. U.S.A. 2014;111 (8):3032-7. doi: 10.1073/pnas.1314421111. PubMed PMID:24516159 PubMed Central PMC3939919.
  84. Shaw, K, Amstutz, U, Hildebrand, C, Rassekh, SR, Hosking, M, Neville, K et al.. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer. 2014;61 (6):1055-62. doi: 10.1002/pbc.24932. PubMed PMID:24474498 .
  85. Martin, DD, Heit, RJ, Yap, MC, Davidson, MW, Hayden, MR, Berthiaume, LG et al.. Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of huntingtin. Hum. Mol. Genet. 2014;23 (12):3166-79. doi: 10.1093/hmg/ddu027. PubMed PMID:24459296 PubMed Central PMC4030772.
  86. de Haan, W, Bhattacharjee, A, Ruddle, P, Kang, MH, Hayden, MR. ABCA1 in adipocytes regulates adipose tissue lipid content, glucose tolerance, and insulin sensitivity. J. Lipid Res. 2014;55 (3):516-23. doi: 10.1194/jlr.M045294. PubMed PMID:24443560 PubMed Central PMC3934735.
  87. Towfic, F, Funt, JM, Fowler, KD, Bakshi, S, Blaugrund, E, Artyomov, MN et al.. Comparing the biological impact of glatiramer acetate with the biological impact of a generic. PLoS ONE. 2014;9 (1):e83757. doi: 10.1371/journal.pone.0083757. PubMed PMID:24421904 PubMed Central PMC3885444.
  88. Lopes, C, Ribeiro, M, Duarte, AI, Humbert, S, Saudou, F, Pereira de Almeida, L et al.. IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice. Mol. Neurobiol. 2014;49 (3):1126-42. doi: 10.1007/s12035-013-8585-5. PubMed PMID:24347322 .
  89. Parsons, MP, Kang, R, Buren, C, Dau, A, Southwell, AL, Doty, CN et al.. Bidirectional control of postsynaptic density-95 (PSD-95) clustering by Huntingtin. J. Biol. Chem. 2014;289 (6):3518-28. doi: 10.1074/jbc.M113.513945. PubMed PMID:24347167 PubMed Central PMC3916553.
  90. Milnerwood, AJ, Parsons, MP, Young, FB, Singaraja, RR, Franciosi, S, Volta, M et al.. Memory and synaptic deficits in Hip14/DHHC17 knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2013;110 (50):20296-301. doi: 10.1073/pnas.1222384110. PubMed PMID:24277827 PubMed Central PMC3864353.
  91. Semaka, A, Hayden, MR. Evidence-based genetic counselling implications for Huntington disease intermediate allele predictive test results. Clin. Genet. 2014;85 (4):303-11. doi: 10.1111/cge.12324. PubMed PMID:24256063 .
  92. Madadi, P, Amstutz, U, Rieder, M, Ito, S, Fung, V, Hwang, S et al.. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. J Popul Ther Clin Pharmacol. 2013;20 (3):e369-96. . PubMed PMID:24214521 .
  93. Wan, J, Savas, JN, Roth, AF, Sanders, SS, Singaraja, RR, Hayden, MR et al.. Tracking brain palmitoylation change: predominance of glial change in a mouse model of Huntington's disease. Chem. Biol. 2013;20 (11):1421-34. doi: 10.1016/j.chembiol.2013.09.018. PubMed PMID:24211138 PubMed Central PMC3880188.
  94. Carleton, BC, Ross, CJ, Bhavsar, AP, Amstutz, U, Pussegoda, K, Visscher, H et al.. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. Clin. Pharmacol. Ther. 2014;95 (3):253. doi: 10.1038/clpt.2013.219. PubMed PMID:24193170 .
  95. Fisher, ER, Hayden, MR. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov. Disord. 2014;29 (1):105-14. doi: 10.1002/mds.25717. PubMed PMID:24151181 .
  96. Franciosi, S, Shim, Y, Lau, M, Hayden, MR, Leavitt, BR. A systematic review and meta-analysis of clinical variables used in Huntington disease research. Mov. Disord. 2013;28 (14):1987-94. doi: 10.1002/mds.25663. PubMed PMID:24142393 .
  97. Kang, MH, Zhang, LH, Wijesekara, N, de Haan, W, Butland, S, Bhattacharjee, A et al.. Regulation of ABCA1 protein expression and function in hepatic and pancreatic islet cells by miR-145. Arterioscler. Thromb. Vasc. Biol. 2013;33 (12):2724-32. doi: 10.1161/ATVBAHA.113.302004. PubMed PMID:24135019 .
  98. Ehrnhoefer, DE, Skotte, NH, Ladha, S, Nguyen, YT, Qiu, X, Deng, Y et al.. p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Hum. Mol. Genet. 2014;23 (3):717-29. doi: 10.1093/hmg/ddt458. PubMed PMID:24070868 .
  99. Pouladi, MA, Morton, AJ, Hayden, MR. Choosing an animal model for the study of Huntington's disease. Nat. Rev. Neurosci. 2013;14 (10):708-21. doi: 10.1038/nrn3570. PubMed PMID:24052178 .
  100. Semaka, A, Kay, C, Doty, CN, Collins, JA, Tam, N, Hayden, MR et al.. High frequency of intermediate alleles on Huntington disease-associated haplotypes in British Columbia's general population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2013;162B (8):864-71. doi: 10.1002/ajmg.b.32193. PubMed PMID:24038799 .
Search PubMed